Septerna to Participate in Upcoming Investor Conferences
Septerna (Nasdaq: SEPN) announced that management will participate in four investor conferences before the end of 2026 through fireside chats.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Septerna (Nasdaq: SEPN) announced that management will participate in four investor conferences before the end of 2026 through fireside chats.
The schedule includes Guggenheim in Boston on November 10, Stifel in New York on November 11, UBS in London on November 16, and Evercore in Miami on December 1. Live webcasts will be available through the company’s investor website and archived for at least 30 days after each presentation.
Details
News Market Reaction – SEPN
On Nov 3, the day this news came out, SEPN closed 1.16% above the previous close. Argus tracked a peak move of +5.8% during that session. Our momentum scanner recorded 23 alerts in the available session data.
Data tracked by StockTitan Argus for the Nov 3 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026:
Guggenheim 3rd Annual Healthcare Innovation Conference – Boston
Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m. ET
Stifel 2026 Healthcare Conference – New York
Fireside chat on Wednesday, November 11, 2026, at 1:20 p.m. ET
UBS Global Biopharma Conference – London
Fireside chat on Monday, November 16, 2026, at 2:00 p.m. GMT
9th Annual Evercore Healthcare Conference – Miami
Fireside chat on Tuesday, December 1, 2026, at 7:55 a.m. ET
A live webcast of each presentation will be available in the investors section of the company’s website at www.septerna.com. The webcasts will be archived for at least 30 days following the presentation.
About Septerna
Septerna, Inc. is a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers advancing cutting-edge science to unlock the full potential of GPCR therapies for patients with significant unmet needs. The company’s proprietary Native Complex Platform® is designed to enable new approaches to GPCR drug discovery and has led to the development of a diverse pipeline of novel oral small molecule drug candidates. Septerna is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. For more information, please visit www.septerna.com.
Investor Contact:
Renee Leck, THRUST
renee@thrustsc.com
Media Contact:
Carly Scaduto, THRUST
carly@thrustsc.com
